
The START Center for Cancer Research (“START”) is the world’s largest early phase site network, fully dedicated to oncology clinical research. Throughout our history, START has provided hope to cancer patients in global community practices by offering "Hope Through Access” to cutting edge trials throughout the United States and Europe.
We are seeking a Hematology Advanced Practice Provider / Nurse Practitioner
This role supports protocol-compliant patient care and clinical trial execution for Phase I and other early-phase oncology studies. Functioning as a sub-investigator under the supervision of the Principal Investigator (PI), the APP/NP extends clinical capacity, supports screening and study visits, and enhances care coordination while preserving core investigator responsibilities specific to early-phase research.
Work Schedule: Monday-Friday, 8:00am-5:00pm
Location: 800 Foremost Dr SE, Grand Rapids, Michigan,49546
Essential Responsibilities:
Required Education and Experience:
Preferred Education and Experience:
More About START
START clinical trial sites have conducted more than 1,000 early-phase clinical trials, including dozens of therapies that were approved by the FDA or EMA. START represents the world’s largest roster of early-phase principal investigators across its Network of clinical trial sites. Committed to accelerating passage from trials to treatments, START delivers hope to patients, families, and physicians around the world via our mission of “Hope Through Access”.
Learn more at STARTresearch.com
Ready to be part of a team changing the future of cancer treatment?
Join us in our mission to conquer cancer, one clinical trial at a time. Your expertise and dedication can help us bring hope and healing to patients worldwide. Please submit your application online.
We are an equal opportunity employer that welcomes and encourages diversity in the workplace. We do not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.

Deeply rooted in community oncology centers globally, the START Center for Cancer Research ("START") provides patients with access to specialized Phase 1 clinical trials for novel anti-cancer agents. With research sites in the United States and in Spain, Portugal, and Ireland, START’s clinical trial sites have conducted more than 1,500 early phase clinical trials, including for 45 therapies that have gained FDA/EMA approval. Founded in Texas in 2007, START today boasts 30+ Principal Investigators (PIs) across its worldwide clinical trial sites. With over 100,000+ square feet of world-class research facilities, START offers patients comprehensive treatment plans that include multi-specialty services, genetic profiling of tumors, targeted therapies, state-of-the-art treatment technology, and advanced access to clinical research options. START is committed to accelerating passage from trials to treatments, and to delivering hope to patients, families, and physicians around the world.